Purchase CD Products
FDALive Interactive CD Purchasing and Licensing Agreement: Please read before selecting this item
Federal law(Title 17 USC, Sections 501 and 506) provides severe civil and criminal penalties for unauthorized use of this product or service. Reproduction, distribution, redistribution and exhibition of FDALive products or services for other than office use is strictly forbidden. Criminal copyright infringements prosecuted by the Federal Bureau of Investigation, and may constitute a felony with a penalty of five years in prison and possible fines of US $250,000.
The product or service you are about to purchase is licensed to the purchasing organization for private use only, all other use is strictly prohibited, without the permission Of Video On Location, Inc.
All Rights Reserved. Copyright 1989-2020, Video On Location, Inc.
- Oncologic Drugs Advisory Committee
Meeting Date: 2/9/21-2/9/21
The committee will discuss supplemental biologics license application (sBLA) 125514/s-089, for KEYTRUDA (pembrolizumab), submitted by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. The proposed indication (use) for this product is for the treatment of patients with high-risk, early-stage triple-negative breast cancer, in combination with chemotherapy as neoadjuvant treatment, then as a single agent as adjuvant treatment after surgery. The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform.
|Location:||Please note that due to the impact of this COVID-19 pandemic, all meeting participants will be joining this advisory committee meeting via an online teleconferencing platform.||Related News Links:||Not Available|